<DOC>
	<DOCNO>NCT02978547</DOCNO>
	<brief_summary>This single arm , non-randomized phase II study neoadjuvant metformin resectable PDAC . Twenty patient enrol treated metformin 500 mg BD minimum 7 day , 2 day prior surgery . Patients undergo laboratory investigation baseline , prior surgery 4-10 week surgery . Patients eligible consented optional MRI substudy undergo diffusion-weighted MRI 1 14 day surgery . At surgery , resect tumour normal tissue collect bank . FFPE specimen use sectioning , histological analysis IHC Ki67 ( cell proliferation marker ) , pAMPK , ACC target , p53 mTOR target , apoptotic marker ( Bax , Bcl-2 , caspases 3 , 8 9 ) . Fresh frozen tumour match normal tissue sample use western blot analysis insulin IGF receptor , total activate ERK Akt , RNAseq analysis . Pre-metformin biopsy sample retrieve molecular analysis . Fasting blood sample baseline surgery analyze glucose insulin level . Plasma whole blood also process banked circulate tumour DNA analysis . Urine sample send metabolomic profiling .</brief_summary>
	<brief_title>The Effects Neoadjuvant Metformin Tumour Cell Proliferation Tumour Progression Pancreatic Ductal Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Age great equal 18 year day study consent Pathologic diagnosis PDAC 2 pretreatment core biopsy sample available analysis . Patients suspect PDAC without pathologic diagnosis must undergo confirmatory biopsy endoscopic ultrasound guidance . Resectable disease base standard image criterion Surgery plan â‰¥ 2 week study entry Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Adequate hematologic , renal , hepatic function measure follow laboratory assessment conduct within 7 day prior initiation study treatment : Total bilirubin &lt; 1.5 time upper limit normal ( ULN ) Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 2.5 time ULN Lipase &lt; 1.5 time ULN Serum creatinine &lt; 1.5 time ULN Glomerular filtration rate &gt; 30 mL/min/1.73 m2 accord modify diet renal disease abbreviate formula International normalized ratio ( INR ) prothrombin time ( PT ; PTINR ) partial thromboplastin time ( PTT ) &lt; 1.5 time ULN Platelet count &gt; 100000 /mm3 , hemoglobin ( &gt; 9 g/dL , absolute neutrophil count &gt; 1500/mm3 . Baseline fast glucose &lt; 13.9 mmol/L No prior chemotherapy radiotherapy PDAC Serum lactate level within normal range assess within 7 day prior initiation study treatment MRI substudy : Signed informed consent optional MRI substudy No contraindication MRI Presence locally unresectable disease distant metastases Treatment metformin antihyperglycemic agent within previous 6 month Known allergy contraindication metformin Not fit surgery Planned , receive , neoadjuvant treatment type</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Resectable pancreatic ductal adenocarcinoma</keyword>
	<keyword>PDAC</keyword>
	<keyword>Metformin</keyword>
</DOC>